Form 4: Boston Scientific EVP Sells Shares After Option Exercise

Boston Scientific's EVP & Group President of Cardiology, Joseph Michael Fitzgerald, exercised stock options and subsequently sold a portion of his common stock holdings.

Summary

• Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp (BSX), reported transactions involving company common stock.
• On September 2, 2025, Fitzgerald exercised stock options to acquire 50,000 shares of common stock at an exercise price of $26.15 per share.
• Concurrently, he sold 21,830 shares at a weighted average price of $104.886 per share and an additional 28,170 shares at a weighted average price of $105.8486 per share.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Fitzgerald directly holds 178,342 shares of common stock and indirectly holds 5,234 shares through a child (beneficial ownership disclaimed).
• He also holds 100,000 derivative securities in the form of stock options with an expiration date of December 1, 2027.

Sentiment

Score: 5

Explanation: The transactions are neutral as they represent a planned exercise of options and subsequent sale of shares under a Rule 10b5-1 plan, which is a common practice for executives to manage their equity compensation and liquidity.

Positives

• The executive realized significant gains by exercising stock options at a price of $26.15 and selling the acquired shares at weighted average prices of $104.886 and $105.8486.
• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned and transparent approach to managing equity holdings.

Negatives

• The sale of 50,000 shares by a key executive, even if planned, represents a reduction in direct equity exposure to the company.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially leading to short-term price pressure if interpreted as a lack of confidence, though this is mitigated by the pre-planned nature.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 5,234 shares held by his child, which are reported as indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be viewed as a slight negative signal, but the pre-planned nature under a 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Options, Joseph Michael Fitzgerald, 10b5-1 Plan, Medical Devices, Cardiology